Regeneron Financial Statements From 2010 to 2022

REGN
 Stock
  

USD 622.15  8.48  1.34%   

Regeneron Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Regeneron Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Regeneron Pharmaceuticals financial statements helps investors assess Regeneron Pharmaceuticals' valuation, profitability, and current liquidity needs.
We have found one hundred nine available trending fundamental ratios for Regeneron Pharmaceuticals, which can be analyzed and compared to other ratios and to its competitors. We recommend to check out Regeneron Pharmaceuticals' recent fundamental drivers against the all of the trends between 2010 and 2022.
Net Income Per Employee is expected to rise to about 840.4 K this year. Revenue Per Employee is expected to rise to about 1.7 M this year.
  
Check Regeneron Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regeneron main balance sheet or income statement drivers, such as Direct Expenses of 2.6 B, Consolidated Income of 869.6 M or Cost of Revenue of 291 M, as well as many exotic indicators such as Interest Coverage of 168, Long Term Debt to Equity of 0.11 or Calculated Tax Rate of 14.47. Regeneron financial statements analysis is a perfect complement when working with Regeneron Pharmaceuticals Valuation or Volatility modules. It can also supplement Regeneron Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Regeneron Pharmaceuticals Technical models . Additionally, take a look at the analysis of Regeneron Pharmaceuticals Correlation against competitors.

Regeneron Pharmaceuticals Revenues

17.34 Billion

Regeneron Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets27.4 B25.4 B9.9 B
Increasing
Slightly volatile
Cash and Equivalents3.1 B2.9 B1.2 B
Increasing
Slightly volatile
Investments1.3 B1.2 B954 M
Increasing
Slightly volatile
Investments Current488.9 M453.1 M335.7 M
Increasing
Slightly volatile
Investments Non Current839.2 M777.8 M618.2 M
Increasing
Slightly volatile
Deferred RevenueB956.2 M702.4 M
Increasing
Slightly volatile
Property Plant and Equipment NetB1.9 B1.4 B
Increasing
Slightly volatile
Inventory387.8 M359.4 M255.9 M
Increasing
Slightly volatile
Tax Assets801.4 M742.8 M595.8 M
Increasing
Slightly volatile
Trade and Non Trade Receivables1.6 B1.5 B1.2 B
Increasing
Slightly volatile
Trade and Non Trade Payables853.6 M791.2 M587.7 M
Increasing
Slightly volatile
Total Liabilities7.2 B6.7 BB
Increasing
Slightly volatile
Shareholders Equity20.3 B18.8 BB
Increasing
Slightly volatile
Accumulated Retained Earnings Deficit1.7 B1.6 B838.8 M
Increasing
Slightly volatile
Accumulated Other Comprehensive Income(11.9 M)(11.6 M)(2.3 M)
Decreasing
Slightly volatile
Current Assets15.1 B14 B5.4 B
Increasing
Slightly volatile
Assets Non Current3.7 B3.4 B2.6 B
Increasing
Slightly volatile
Current Liabilities4.2 B3.9 B1.5 B
Increasing
Slightly volatile
Liabilities Non Current1.2 B1.2 B989.1 M
Increasing
Slightly volatile
Total Debt349.8 M431 M430.3 M
Increasing
Stable
Debt Current123.6 M114.5 M96.9 M
Increasing
Slightly volatile
Debt Non Current287.9 M316.4 M367.5 M
Decreasing
Stable
Shareholders Equity USD4.3 BB3.1 B
Increasing
Slightly volatile
Cash and Equivalents USD392.4 M481.7 M500.4 M
Increasing
Stable
Total Debt USD349.8 M431 M430.3 M
Increasing
Stable
Accounts Payable608.5 M564 M229.4 M
Increasing
Slightly volatile
Receivables6.5 BBB
Increasing
Slightly volatile
Inventories2.1 BB793.4 M
Increasing
Slightly volatile

Regeneron Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues17.3 B16.1 BB
Increasing
Slightly volatile
Cost of Revenue291 M269.7 M223.7 M
Increasing
Slightly volatile
Selling General and Administrative Expense1.1 B1.1 B779.5 M
Increasing
Slightly volatile
Research and Development ExpenseB1.8 B1.5 B
Increasing
Slightly volatile
Operating Expenses3.1 B2.9 B2.2 B
Increasing
Slightly volatile
Interest Expense6.6 M6.5 M16.6 M
Decreasing
Slightly volatile
Income Tax Expense421.7 M390.9 M303.4 M
Increasing
Slightly volatile
Consolidated Income869.6 M806 M614.9 M
Increasing
Slightly volatile
Net Income8.7 B8.1 B2.2 B
Increasing
Slightly volatile
Net Income Common Stock869.6 M806 M614.9 M
Increasing
Slightly volatile
Weighted Average Shares98.1 M105.7 M100.7 M
Increasing
Slightly volatile
Weighted Average Shares Diluted105.3 M112.2 M109.5 M
Increasing
Slightly volatile
Earning Before Interest and Taxes EBIT1.3 B1.2 B934.8 M
Increasing
Slightly volatile
Revenues USD4.7 B4.4 B3.4 B
Increasing
Slightly volatile
Net Income Common Stock USD869.6 M806 M614.9 M
Increasing
Slightly volatile
Earning Before Interest and Taxes USD1.3 B1.2 B934.8 M
Increasing
Slightly volatile
Gross Profit4.4 B4.1 B3.2 B
Increasing
Slightly volatile
Operating Income9.7 B8.9 B2.6 B
Increasing
Slightly volatile
Direct Expenses2.6 B2.4 B688 M
Increasing
Slightly volatile

Regeneron Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow Investment Acquisitions and Disposals(631.4 M)(615.2 M)(334.7 M)
Decreasing
Slightly volatile
Net Cash Flow from Financing(1 B)(1 B)(379 M)
Decreasing
Slightly volatile
Issuance Repayment of Debt Securities (47.9 M)(46.7 M)(6.5 M)
Decreasing
Slightly volatile
Issuance Purchase of Equity Shares(19.4 M)(18.9 M)(21.3 M)
Decreasing
Very volatile
Net Cash Flow from Investing(5.5 B)(5.4 B)(1.4 B)
Decreasing
Slightly volatile
Net Cash Flow from Operations7.6 B7.1 B2.1 B
Increasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents(323.3 M)(315 M)(84.2 M)
Decreasing
Slightly volatile
Share Based Compensation543.7 M503.9 M384.2 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion101.7 M94.3 M74 M
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share82.4376.420.8847
Increasing
Slightly volatile
Earnings per Diluted Share77.6571.9719.4902
Increasing
Slightly volatile
Earnings per Basic Share USD8.317.75.8596
Increasing
Slightly volatile
Return on Average Equity58.4954.207425.0929
Increasing
Slightly volatile
Return on Average Assets40.9137.913917.295
Increasing
Slightly volatile
Return on Invested Capital0.250.230.184
Increasing
Slightly volatile
Gross Margin98.2384.833692.9841
Decreasing
Slightly volatile
Profit Margin54.2150.245521.3775
Increasing
Slightly volatile
EBITDA Margin64.8860.131830.5956
Increasing
Slightly volatile
Return on Sales0.270.25(0.0487)
Increasing
Slightly volatile
Asset Turnover0.690.75460.6879
Increasing
Very volatile
Enterprise Value over EBITDA25.7123.8322.7777
Increasing
Slightly volatile
Enterprise Value over EBIT27.1925.224.7992
Increasing
Slightly volatile
Price to Earnings Ratio41.6938.6442.5827
Increasing
Stable
Sales per Share16415257.2986
Increasing
Slightly volatile
Price to Sales Ratio13.579.114.0277
Decreasing
Slightly volatile
Price to Book Value7.477.8310.2381
Decreasing
Slightly volatile
Debt to Equity Ratio0.210.14380.231
Decreasing
Slightly volatile
Current Ratio4.273.56394.15
Decreasing
Stable
Free Cash Flow per Share66.6561.772916.3247
Increasing
Slightly volatile
Book Value per Share41.138.0930.4087
Increasing
Slightly volatile
Tangible Assets Book Value per Share64.4259.7148.0799
Increasing
Slightly volatile
Total Assets Per Share25323492.6922
Increasing
Slightly volatile
Cash Flow Per Share70.3165.160519.444
Increasing
Slightly volatile
Return on Investment56.051.907226.8972
Increasing
Slightly volatile
Operating Margin60.0655.66826.8301
Increasing
Slightly volatile
Calculated Tax Rate14.4713.4092.1886
Increasing
Slightly volatile
Receivables Turnover3.383.29799.1319
Decreasing
Slightly volatile
Inventory Turnover1.311.26041.4142
Decreasing
Slightly volatile
PPandE Turnover3.84.79483.0981
Increasing
Slightly volatile
Cash and Equivalents Turnover5.56.32835.176
Increasing
Slightly volatile
Accounts Payable Turnover34.6330.92231.9359
Decreasing
Stable
Accrued Expenses Turnover11.8810.384211.1332
Decreasing
Slightly volatile
Interest Coverage16815675.021
Increasing
Slightly volatile
Long Term Debt to Equity0.110.10550.2179
Decreasing
Slightly volatile
Quick Ratio3.392.98313.1617
Decreasing
Slightly volatile
Net Current Assets as percentage of Total Assets37.1539.640238.5518
Increasing
Very volatile
Revenue to Assets0.590.63190.5982
Increasing
Stable

Regeneron Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Earnings before Tax1.3 B1.2 B918.1 M
Increasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization EBITDA10.4 B9.7 B2.8 B
Increasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization USD1.4 B1.3 BB
Increasing
Slightly volatile
Market Capitalization37.6 B34.8 B31.9 B
Increasing
Slightly volatile
Enterprise Value37.1 B34.4 B31.6 B
Increasing
Slightly volatile
Invested Capital435.5 M424.4 M1.6 B
Decreasing
Slightly volatile
Average Equity4.1 B3.8 B2.9 B
Increasing
Slightly volatile
Average Assets6.3 B5.8 B4.5 B
Increasing
Slightly volatile
Invested Capital AverageB4.7 B3.7 B
Increasing
Slightly volatile
Tangible Asset Value6.8 B6.3 B4.9 B
Increasing
Slightly volatile
Free Cash Flow933.6 M865.3 M594 M
Increasing
Slightly volatile
Working Capital1.9 B1.7 B1.6 B
Increasing
Slightly volatile
Revenue Per Employee1.7 M1.6 M922.1 K
Increasing
Slightly volatile
Net Income Per Employee840.4 K778.9 K275.4 K
Increasing
Slightly volatile

Regeneron Fundamental Market Drivers

Forward Price Earnings14.38
Short Percent Of Float2.76%
Average Daily Volume Last 10 Day659.93k
Shares Short Prior Month2.58M
Average Daily Volume In Three Month668.23k
Date Short Interest15th of July 2022
Fifty Day Average601.23
Two Hundred Day Average633.45

Regeneron Upcoming Events

Upcoming Quarterly Report4th of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End4th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

About Regeneron Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Regeneron Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Regeneron Pharmaceuticals investors use historical funamental indicators, such as Regeneron Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although Regeneron Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Regeneron Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Regeneron Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Regeneron Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Regeneron Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Deferred Revenue956.2 MB
Cost of Revenue269.7 M291 M
Revenues16.1 B17.3 B
Revenue to Assets 0.63  0.59 
Revenue Per Employee1.6 M1.7 M
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The companys products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema myopic choroidal neovascularization and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinomaPraluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults REGEN-COV for covid-19 and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi Bayer Teva Pharmaceutical Industries Ltd. Mitsubishi Tanabe Pharma Corporation Alnylam Pharmaceuticals, Inc. Roche Pharmaceuticals and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited Intellia Therapeutics, Inc. Biomedical Advanced Research Development Authority and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Regeneron Pharmaceuticals without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Financial Widgets Now

   

Financial Widgets

Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
All  Next Launch Module

Currently Active Assets on Macroaxis

Additionally, take a look at the analysis of Regeneron Pharmaceuticals Correlation against competitors. Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.

Complementary Tools for Regeneron Stock analysis

When running Regeneron Pharmaceuticals price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
-0.73
Market Capitalization
68.7 B
Quarterly Revenue Growth YOY
-0.44
Return On Assets
0.18
Return On Equity
0.32
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Regeneron Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.